Plain-English translation of NCT05645718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach called Pedi-cRIB—a combination of four medications (mini-hyper-CVD, , , and ) given in a specific sequence—for children and young adults whose acute lymphoblastic leukemia has returned or did not respond to their first treatment. The goal is to see how well this combination works at putting the cancer into remission and how safe it is.
Many children with relapsed or hard-to-treat acute lymphoblastic leukemia cannot receive standard first-line treatments because of heart damage, allergies, or other health issues. This trial offers a new option designed specifically for these patients.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination in repeating cycles, with each cycle lasting 28 days followed by a 7-day rest period with no treatment. The exact schedule depends on whether your leukemia has spread to your brain and spinal fluid. You will have regular blood tests, bone marrow tests, and imaging scans to monitor how well the treatment is working and watch for side effects. The trial is being conducted at M.D. Anderson Cancer Center and plans to enroll 27 participants.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States